We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Dynavax Technologies Corp | NASDAQ:DVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -0.74% | 12.01 | 11.61 | 12.44 | 12.16 | 11.92 | 12.03 | 1,081,192 | 00:35:04 |
From Jun 2019 to Jun 2024
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to report third quarter 2009 financial results after the market closes on Thursday, October 22, 2009.
The Company also plans to host a webcast of a conference call on Thursday, October 22, 2009 at 4:30 pm EDT (1:30 pm PDT). To access the live audio webcast and the subsequent archived audio recording of the presentation, please log onto Dynavax’s website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
1 Year Dynavax Technologies Chart |
1 Month Dynavax Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
